A field-tested LOI framework built for buyers and sellers navigating drug testing company acquisitions — covering DOT compliance, MRO revenue, client concentration, and SBA-compatible deal structures in the $1M–$5M revenue range.
An LOI for a drug testing services acquisition is not a generic document — it must account for the unique revenue architecture of the industry, where pass-through lab charges can distort top-line figures, where DOT and SAMHSA regulatory standing determines operational continuity, and where client relationships are often tied personally to the owner. A well-drafted LOI establishes the purchase price on defensible EBITDA isolated from pass-through costs, locks down the due diligence scope needed to verify regulatory compliance and contract durability, and structures earnout or seller note provisions that protect the buyer if key employer accounts churn post-close. For sellers, the LOI is the moment to clarify how collection revenue is distinguished from lab pass-throughs, assert the value of DOT consortium management contracts, and negotiate transition terms that are realistic given the compliance handoff required. This guide walks both parties through each LOI section with language specific to drug testing transactions, flags the terms most commonly left ambiguous, and identifies the mistakes that cause deals to collapse or reprice during due diligence.
Find Drug Testing Services Businesses to AcquireParties and Transaction Structure
Identifies the buyer entity, seller entity, and the proposed structure of the transaction — asset purchase, equity purchase, or hybrid. For drug testing businesses, asset purchases are most common because buyers want to cherry-pick collector certifications, client contracts, and equipment while leaving behind unknown regulatory liabilities. Specify whether the acquisition includes collection site leases, mobile collection vehicles, chain-of-custody software licenses, and existing lab and MRO vendor agreements.
Example Language
This Letter of Intent is entered into between [Buyer Entity Name], a [state] [LLC/Corporation] ('Buyer'), and [Seller Entity Name], a [state] [LLC/Corporation] ('Seller'), regarding the proposed acquisition of substantially all assets of Seller's drug testing services business, including but not limited to employer client contracts, DOT consortium management agreements, collector certifications, chain-of-custody software licenses, collection equipment, and associated goodwill. The transaction is contemplated as an asset purchase. Equity instruments, pending regulatory citations, and any liabilities arising from pre-closing DOT or SAMHSA audit findings are expressly excluded from the purchased assets unless otherwise agreed in writing.
💡 Sellers frequently prefer equity sales for tax efficiency, but buyers in drug testing deals almost always insist on asset purchases to avoid inheriting regulatory exposure. If the seller resists, consider a hybrid structure where the buyer acquires assets but the seller indemnifies for pre-closing compliance liabilities for a defined period. Clearly enumerate which collector certifications and lab agreements transfer — some SAMHSA-certified lab contracts include change-of-control provisions that require consent, and surfacing this early avoids surprises at closing.
Purchase Price and EBITDA Basis
States the proposed total consideration and the financial basis on which it was calculated. Drug testing businesses require explicit definition of EBITDA that strips out pass-through lab and MRO charges, which can represent 40–60% of gross revenue but carry near-zero margin. The LOI should state whether the multiple is applied to trailing twelve months, seller's discretionary earnings, or normalized EBITDA, and should reference the specific revenue lines being excluded.
Example Language
Buyer proposes a total purchase price of $[X], representing approximately [3.5x–6.0x] of Seller's trailing twelve-month EBITDA of approximately $[Y], as normalized to exclude pass-through laboratory processing fees, third-party MRO review costs, and one-time expenses. For purposes of this LOI, EBITDA is calculated on collection service revenue, DOT consortium administration fees, and value-added compliance reporting revenue only, and excludes gross-up revenue attributable to specimen laboratory charges billed and remitted at cost. The purchase price is subject to adjustment following completion of financial due diligence and confirmation of the revenue mix between owned-margin services and pass-through laboratory charges.
💡 The most common valuation dispute in drug testing deals is the seller including pass-through lab revenue in EBITDA calculations, which inflates the apparent margin base. Buyers should insist the LOI explicitly define which revenue streams are included in the EBITDA multiple basis. If the seller has DOT consortium management contracts that generate recurring administrative fees, those should be specifically called out as high-quality revenue deserving a premium multiple. Agree in the LOI on whether owner compensation addbacks are capped and whether any MRO physician fees paid to a related party are normalized.
Deal Structure and Consideration Breakdown
Specifies how the purchase price will be funded and delivered, including the split between cash at closing, SBA-financed proceeds, seller note, and any earnout tied to post-closing performance. Drug testing acquisitions frequently use SBA 7(a) financing given the recurring revenue model and asset-light profile, with seller notes and earnouts used to bridge valuation gaps related to client retention risk.
Example Language
The proposed consideration will be structured as follows: (i) cash at closing of approximately $[X], funded through a combination of buyer equity injection of not less than 10% of total project costs and SBA 7(a) loan proceeds; (ii) a seller promissory note of $[Y], equal to approximately 5–10% of the purchase price, bearing interest at [prime + 1–2%], payable over 24 months and subordinated to the senior SBA lender; and (iii) a performance-based earnout of up to $[Z], payable over 12 months post-closing, contingent upon retention of employer client accounts representing no less than 85% of trailing twelve-month collection revenue, as measured by aggregate collections volume. The earnout calculation will exclude revenue from any new accounts originated by Buyer following closing.
💡 Sellers with strong multi-year employer contracts often push back on earnouts, arguing that client retention risk is priced into the multiple. Buyers should insist on an earnout when any single employer account represents more than 15% of revenue or when client contracts are month-to-month purchase orders rather than signed agreements. For SBA deals, confirm that the lender will allow the seller note and earnout structure — SBA 7(a) guidelines require seller notes to be on full standby for 24 months in most cases. If the seller is also the MRO, consider tying a portion of the earnout to successful MRO transition to a third-party physician partner.
Due Diligence Scope and Period
Defines the categories of information the buyer will examine, the timeline for the due diligence period, and the seller's cooperation obligations. For drug testing businesses, due diligence must specifically address DOT and SAMHSA regulatory compliance history, chain-of-custody documentation practices, collector certification status, and the terms of lab and MRO vendor agreements.
Example Language
Buyer shall have [45–60] days following execution of this LOI to conduct comprehensive due diligence, during which Seller shall provide reasonable access to: (i) three years of financial statements with revenue schedules separating collection fees, MRO review fees, DOT consortium administration revenue, and laboratory pass-through charges; (ii) all employer client contracts, purchase orders, and correspondence, including renewal terms and historical account churn data; (iii) documentation of all DOT, SAMHSA, and state occupational health compliance audits, citations, consent orders, or corrective action plans for the past five years; (iv) collector certification records, DOT Qualified Collector credentials, and any chain-of-custody audit results; (v) lab and MRO vendor agreements including pricing schedules, exclusivity provisions, and assignment or change-of-control clauses; and (vi) technology infrastructure documentation including LIMS or chain-of-custody software licensing agreements and HR system integration capabilities.
💡 Sellers are often reluctant to share client lists before exclusivity is confirmed. Negotiate the right to review anonymized client concentration data — industry type, contract length, and revenue percentage — before full disclosure. Prioritize regulatory compliance documents early in the diligence period; undisclosed DOT audit findings or expired collector certifications are among the most common deal-killers in this industry. Buyers should also request any correspondence with state health departments regarding collection site licensure, as licensing portability varies significantly by state.
Exclusivity and No-Shop Period
Establishes the period during which the seller agrees not to solicit or entertain competing offers, giving the buyer time to complete due diligence and finalize financing. This is a critical provision for drug testing acquisitions where SBA loan approval timelines and regulatory review of license transfers can extend the path to closing.
Example Language
In consideration of the time and expense incurred by Buyer in conducting due diligence and arranging financing, Seller agrees that for a period of [60] days following full execution of this LOI ('Exclusivity Period'), Seller will not, directly or indirectly, solicit, encourage, or negotiate with any third party regarding the sale, merger, or other disposition of the Business or its material assets. Seller will promptly notify Buyer of any unsolicited inquiries received during the Exclusivity Period. The Exclusivity Period may be extended by mutual written agreement if SBA lender approval, state license transfer, or regulatory confirmation of collector certification portability requires additional time.
💡 Sixty days is a reasonable starting point but may need extension if the deal involves SBA financing, which typically adds 30–45 days beyond a conventional close. Sellers should negotiate a drop-dead date after which exclusivity lapses if the buyer has not delivered a signed purchase agreement or demonstrated financing commitment. Buyers acquiring a DOT-authorized collection network should use the exclusivity period to proactively engage with the SBA lender's healthcare underwriting team and confirm whether state occupational health licenses require a new application or can be transferred by assignment.
Transition, Non-Compete, and Employment Terms
Outlines the seller's post-closing obligations including a transition assistance period, non-compete covenant, and any employment or consulting arrangement. Drug testing businesses have acute owner dependency risk — sellers frequently manage key employer accounts personally, hold MRO credentials, or serve as the primary DOT compliance contact — making transition planning a core LOI term rather than an afterthought.
Example Language
Seller agrees to provide transition assistance for a period of [12–24] months following closing, including introduction of Buyer to all employer clients and government agency contacts, transfer of DOT consortium management responsibilities, and training of Buyer's designated staff on chain-of-custody protocols, SAMHSA-compliant collection procedures, and electronic result reporting workflows. If Seller currently performs MRO reviews, Seller will cooperate in identifying and onboarding a qualified replacement MRO physician within [90] days of closing. Seller further agrees to a non-compete covenant prohibiting engagement in drug testing collection services, DOT consortium management, or employer compliance program administration within [50] miles of any current collection site for a period of [3–5] years post-closing. Seller may be offered a consulting agreement at a rate of $[X] per month during the transition period, which shall be structured separately from and not constitute an offset to the purchase price.
💡 Sellers who are also credentialed MROs present the highest transition risk. If the seller holds MRO certification and personally reviews results for employer accounts, budget for a 90-day parallel review period with a contracted MRO physician and factor MRO replacement costs into your valuation model. Non-compete geography should be defined by collection site addresses rather than a radius from the seller's home, since drug testing markets are defined by employer locations and travel logistics. Buyers using SBA financing should confirm that the non-compete term and geographic scope meet SBA requirements, which typically require a minimum 2-year covenant.
Conditions to Closing
Lists the specific conditions that must be satisfied before the transaction closes, including financing approval, regulatory confirmations, client consent requirements, and satisfactory completion of due diligence. Drug testing deals have industry-specific closing conditions related to license portability, lab agreement assignments, and DOT authorization continuity.
Example Language
Closing of the contemplated transaction shall be conditioned upon: (i) Buyer obtaining SBA 7(a) loan commitment on terms acceptable to Buyer; (ii) satisfactory completion of due diligence with no material adverse findings related to DOT or SAMHSA compliance history, collector certification status, or undisclosed regulatory citations; (iii) confirmation that all employer client contracts representing not less than 80% of trailing twelve-month collection revenue are assignable or have been novated to Buyer without termination rights triggered; (iv) assignment or re-execution of all SAMHSA-certified laboratory vendor agreements and MRO service agreements on terms no less favorable than those currently in effect; (v) transfer or re-issuance of all state occupational health collection site licenses required for continued operation; and (vi) execution of a mutually acceptable asset purchase agreement, transition services agreement, and non-compete covenant.
💡 Client contract assignability is the most frequently overlooked closing condition in drug testing deals. Many employer agreements — especially with transportation companies or government agencies — contain anti-assignment clauses or require counterparty consent. Identify these contracts early and build consent outreach into the due diligence timeline rather than the closing week. For DOT-regulated employers, confirm whether consortium membership transfers automatically or requires new enrollment. Lab agreement assignments often require written consent from the laboratory network; SAMHSA-certified labs sometimes use this leverage to renegotiate pricing at the point of ownership change.
EBITDA Definition and Pass-Through Revenue Exclusion
The single most contested financial term in drug testing LOIs. Sellers often calculate EBITDA on gross revenue including laboratory specimen charges billed to employer clients, which inflates apparent margin. Buyers must insist the LOI define EBITDA as applied only to collection service fees, consortium administration revenue, and proprietary MRO or compliance services — explicitly excluding laboratory pass-through charges that are remitted in full to the SAMHSA-certified lab with no retained margin. A $3M revenue drug testing business may have true EBITDA-eligible revenue of only $1.2M–$1.8M after pass-throughs are stripped.
Client Concentration Threshold and Earnout Trigger
Agree in the LOI on the maximum allowable revenue concentration for any single employer account and the earnout mechanics if concentration risk materializes post-close. Best practice is to cap single-account concentration at 20% of collection revenue and structure a dollar-for-dollar earnout reduction if any account exceeding 10% of revenue terminates within 12 months of closing. Define revenue using collections volume rather than billed amounts to avoid distortion from lab pass-throughs.
Regulatory Compliance Representations and Indemnification Scope
The LOI should establish that the seller will represent at closing that no outstanding DOT audit findings, SAMHSA citations, state occupational health license violations, or HIPAA breaches exist, and that all collector certifications are current. Negotiate the indemnification basket, cap, and survival period specifically for regulatory liabilities — given that DOT enforcement actions can surface 18–24 months after a violation occurred, buyers should seek a 36-month survival period for regulatory indemnification claims, which is longer than the typical 18-month general indemnification window.
Lab and MRO Vendor Agreement Assignment Terms
Confirm in the LOI that the seller will use commercially reasonable efforts to obtain written assignment consent from all SAMHSA-certified laboratory partners and MRO service providers prior to closing, and that failure to obtain consent from a lab generating more than 20% of specimen processing volume is a material closing condition. Negotiate protections if a lab uses the change-of-control as an opportunity to reprice — consider including a walkaway right if lab pricing increases more than 10% as a condition of assignment consent.
Seller Note Standby Provisions and SBA Compliance
If an SBA 7(a) loan is used, the seller note must comply with SBA standby requirements — typically full payment standby for 24 months, meaning the seller cannot receive principal or interest payments during that window. Negotiate the seller note interest rate, which should reflect the standby risk premium — prime plus 1–2% is market. Also confirm the seller note is structured as a subordinated promissory note acceptable to the SBA lender, and clarify whether the earnout is treated as contingent consideration or deferred purchase price for SBA project cost calculations.
Find Drug Testing Services Businesses to Acquire
Enough information to write a strong LOI on day one — free to join.
Drug testing companies in the $1M–$5M revenue range typically trade at 3.5x–6.0x EBITDA, but the multiple applies to normalized EBITDA that excludes pass-through laboratory and MRO costs. Businesses with diversified employer client bases under multi-year contracts, active DOT consortium management programs, and clean regulatory compliance records command the higher end of that range. Businesses with revenue concentration in one or two large accounts, month-to-month employer agreements, or thin margins due to heavy lab pass-throughs typically price at 3.5x–4.5x. Always confirm which revenue streams are included in the EBITDA base before accepting a valuation framed around total gross revenue.
Yes — drug testing services businesses are generally SBA-eligible given their recurring revenue characteristics, essential compliance-driven demand, and asset-light operating models. Most SBA lenders will require a minimum 10% buyer equity injection, personal guarantees, and a seller note on full payment standby for 24 months. The SBA lender will scrutinize the quality of recurring employer contracts and will want to understand the revenue split between owned-margin collection services and pass-through laboratory charges. Work with an SBA lender experienced in healthcare services or occupational health transactions, as underwriting drug testing businesses requires familiarity with DOT regulatory revenue streams.
Beyond standard financial and legal review, drug testing acquisitions require specific attention to: DOT and SAMHSA regulatory compliance history including any citations, corrective action plans, or consent orders in the past five years; current status of all collector certifications and whether they are held by the owner or transferable staff; change-of-control provisions in SAMHSA-certified lab agreements that could trigger repricing; chain-of-custody documentation practices and whether the business uses electronic or paper-based processes; and state-by-state collection site licensure portability, since some states require a new license application under new ownership rather than a simple transfer. Skipping any of these creates post-closing exposure that is difficult to indemnify after the fact.
Seller-MRO situations are among the highest-risk transitions in drug testing acquisitions and must be addressed explicitly in the LOI. Require the seller to commit to identifying and onboarding a qualified replacement MRO physician within 90 days of closing, and specify a parallel review period during which both the seller and the incoming MRO review results to ensure continuity. If employer contracts reference the seller by name as the MRO of record, those contracts may require amendment — identify this early. Consider tying a portion of the purchase price to successful MRO transition rather than paying full consideration at closing when this risk is material.
Non-compete covenants in drug testing deals typically cover a 3–5 year term and a geographic scope defined by the collection site network rather than a broad regional radius. The covenant should prohibit the seller from operating or advising any competing drug testing collection service, DOT consortium, or employer compliance program within a defined distance of each current collection site. If the seller has longstanding personal relationships with transportation companies, construction firms, or healthcare employers, the non-solicitation of clients provision is equally important and should survive for the full non-compete term. For SBA-financed transactions, confirm the non-compete meets SBA minimum standards, which generally require at least a 2-year term.
Start by requesting a revenue schedule that separately itemizes collection service fees, DOT consortium administration fees, MRO review fees charged to employers, and laboratory specimen processing charges billed and remitted to the SAMHSA lab. Apply your EBITDA multiple only to the first three categories — these represent services where the business retains margin. Pass-through lab charges should be excluded from the valuation base entirely. A business reporting $3M in gross revenue might have only $1.4M in true service revenue after lab pass-throughs are removed, and the EBITDA margin on that $1.4M — not the $3M — is what drives your valuation. Sellers who resist this framing should be asked to provide gross margin by revenue line before proceeding.
More Drug Testing Services Guides
More LOI Templates
Get enough diligence data to write a confident LOI from day one.
Create your free accountNo credit card required
For Buyers
For Sellers